Clinical support materials

AMPLIFY video: Fixed- duration CALQUENCE (acalabrutinib) combinations in previously-untreated CLL


International Expert Prof John Seymour presents AMPLIFY trial data evaluating the efficacy and safety of CALQUENCE (acalabrutinib) in combination with venetoclax, with or without obinutuzumab

Found this useful? You might also be interested in:

 

CLL Exchange Bite-sized:
Fixed-duration decision
making in 1L CLL.

BSH Guidelines 2025
for the 1L Treatment of CLL

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

September 2025 I GB-69434